Nivolumab Generics - Manufacturers & Suppliers
Opdivo® (EU & US)
| Product/Composition:- | Nivolumab |
|---|---|
| Strength:- | 40 mg/4 mL (vial); 100 mg/10 mL (vial) |
| Form:- | Intravenous (IV) |
| Reference Brands:- | Opdivo® (EU & US) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology to treat various cancers by blocking the PD-1 receptor, which enhances the immune system’s ability to fight cancer. It is used for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck cancers, and more. Nivolumab is available in intravenous (IV) form in strengths of 40 mg/4 mL and 100 mg/10 mL. It is available in both the US and EU.
Nivolumab (brand name Opdivo®) is a monoclonal antibody used in oncology as an immune checkpoint inhibitor. It works by targeting and blocking the PD-1 receptor on T-cells, which prevents cancer cells from evading the immune system. By doing so, Nivolumab enhances the body's immune response, allowing T-cells to identify and attack cancer cells more effectively. Nivolumab is indicated for the treatment of several cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and others. It is administered as an intravenous (IV) infusion in two available strengths: 40 mg/4 mL and 100 mg/10 mL.